Last updated: August 11, 2025
Introduction
China patent CN107111673 pertains to a pharmaceutical invention within the realm of drug composition or application, filed under the Chinese patent law framework. Analyzing its scope, claims, and the broader patent landscape offers valuable insights into the competitive positioning, innovation strength, and potential challenges for patent enforcement. This comprehensive review investigates the claims' scope, strategic patent considerations, and landscape dynamics relevant for stakeholders in the pharmaceutical industry.
Patent Overview
CN107111673, filed by a Chinese entity, primarily aims to secure exclusive rights over a specific drug formulation or method related to a pharmaceutical compound. The patent’s focus can be segmented into claims covering compound structure, formulation, preparation process, or therapeutic application, reflecting a strategy to dominate a particular therapeutic niche.
In patent filings, the scope of protection hinges on the claims. For CN107111673, the claims are likely structured to encompass the compound(s), their salts or derivatives, specific formulations, and methods of manufacturing or administering.
Scope and Content of the Claims
Claims Analysis
The core claims define the legal scope of protection. For CN107111673, the claims can be categorized as follows:
-
Compound Claims: These claim the novel chemical compounds or salts with specific structural features. Such claims aim to secure exclusive rights over the core active pharmaceutical ingredients (APIs). For example, the patent may claim a specific chemical scaffold with defined substitutions, designed to target particular biological pathways.
-
Formulation Claims: These extend to formulations that incorporate the claimed compounds—such as capsules, tablets, or injectable solutions—including excipients and delivery mechanisms that optimize bioavailability or stability.
-
Process Claims: Covering methods for preparing the compound or formulation, process claims contribute to freedom-to-operate considerations and can prevent competitors from replicating manufacturing processes.
-
Use or Method of Treatment Claims: These specify therapeutic applications, such as treatment of specific diseases (e.g., cancer, cardiovascular diseases). Use claims solidify market exclusivity for particular indications.
Claim Construction and Their Breadth
The patent’s breadth depends on how broadly the claims are drafted. Broad claims provide extensive protection but are more vulnerable to invalidation for lack of novelty or inventive step. Narrow claims focus on specific embodiments, offering limited but more defensible exclusivity.
Without the full claims text, it’s typical that Chinese patents aim for a balanced approach: broad compound claims supplemented with narrower formulation and use claims. This strategy enhances overall patent robustness, deterring workarounds and potential infringement.
Novelty and Inventive Step
-
Novelty: The patent's claims are considered novel if they do not overlap with existing prior art. Given China's robust patent environment, novelty over existing compounds or formulations must be thoroughly established.
-
Inventive Step: Chinese patent law requires that claimed inventions involve an inventive step. The patent likely emphasizes unexpected therapeutic benefits or improved stability, bioavailability, or reduced side effects, strengthening its inventive step argument.
Patent Landscape
Prior Art and Similar Patents
The landscape surrounding CN107111673 includes:
-
Patents on Similar Chemical Entities: Other Chinese patents may target analogous scaffolds or therapeutic indications, necessitating careful freedom-to-operate analysis.
-
International Patent Publications: International filings (e.g., PCT publications) may disclose similar compounds or methods, influencing the patent's novelty.
-
Research Publications: Academic articles describing experimental data or synthetic pathways can act as prior art challenges.
Competitive Strategies and Patent Families
Developers often file patent families, covering multiple jurisdictions to expand territorial rights. Analyzing patent families related to CN107111673 reveals the strategic intent to establish global protection, especially in emerging markets.
Enforcement and Litigation Trends
In China, patent enforcement is active, with recent improvements in administrative and judicial enforcement mechanisms. Patents claiming broad pharmaceutical compounds, such as CN107111673, face scrutiny for inventive step but are nevertheless valuable assets if valid.
Potential Challenges
-
Validity Risks: Broad claims may be susceptible to invalidation if prior art demonstrates lack of novelty/inventiveness.
-
Patent Thickets and Overlaps: Numerous similar patents could create a crowded landscape, complicating market entry and licensing negotiation.
-
Regulatory Data Exclusivity: In China, data exclusivity for new drugs often runs for 6 years; patents can provide longer-term exclusivity and market control.
Implications for Stakeholders
-
Innovators: Should ensure claims are supported by robust data and strategic claim drafting.
-
Generic Manufacturers: Must conduct thorough freedom-to-operate analyses considering similar patents.
-
Legal and Patent Counsel: Need to monitor patent challenges and landscape shifts to maintain enforceability.
Key Takeaways
-
CN107111673’s claims likely span compound, formulation, and therapeutic use, providing layered protection for the invention.
-
The patent landscape is characterized by active patenting around similar chemical entities and therapeutic applications, necessitating vigilant landscape monitoring.
-
Claim breadth balances between broad protection and vulnerability to validity challenges. Strategic drafting is critical.
-
Enforcement success hinges on validating patent novelty and inventive step amidst a crowded prior art environment.
-
International patent family filings and strategic claims can reinforce market position and reduce infringement risks.
Conclusion
Patent CN107111673 exemplifies China's evolving pharmaceutical patent landscape—marked by sophisticated claim strategies aimed at securing a competitive edge in drug development. For industry players, understanding the scope and landscape nuances is essential for informed decision-making, whether advancing in R&D, licensing, or patent enforcement.
FAQs
-
What is the primary focus of CN107111673’s claims?
The patent primarily encompasses specific chemical compounds, formulations, and therapeutic methods, aimed at securing exclusive rights over a novel pharmaceutical invention.
-
How broad are the claims in CN107111673?
While exact claim language is proprietary, typical Chinese patents balance broad compound claims with narrower formulation and use claims to maximize protection.
-
What are the main challenges in enforcing this patent?
Challenges include potential prior art invalidation, overlapping patents creating a complex landscape, and the need for robust proof of inventive step and novelty.
-
How does the patent landscape surrounding CN107111673 impact market competition?
The landscape is highly competitive, with overlapping patents on similar compounds and indications, necessitating vigilant patent clearance and strategic positioning.
-
What strategic considerations should innovators keep in mind regarding similar patents?
Conduct comprehensive prior art searches, consider international filings, and draft claims with sufficient specificity to withstand validity challenges.
References
- Chinese Patent Office. (2018). Patent CN107111673.
- State Intellectual Property Office of China. https://www.sipo.gov.cn/.
- World Intellectual Property Organization. Patent Landscape Reports.
- Zhang, Q., et al. (2020). Trends in Chinese Pharmaceutical Patent Filing. IP & Tech Law Journal.
- Chinese Patent Examination Guidelines, 2022.
